ID   HCST_HUMAN              Reviewed;          93 AA.
AC   Q9UBK5; Q9UBS1; Q9Y3Y0;
DT   29-APR-2008, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   18-JUN-2025, entry version 159.
DE   RecName: Full=Hematopoietic cell signal transducer;
DE   AltName: Full=DNAX-activation protein 10;
DE   AltName: Full=Membrane protein DAP10;
DE   AltName: Full=Transmembrane adapter protein KAP10;
DE   Flags: Precursor;
GN   Name=HCST; Synonyms=DAP10, KAP10, PIK3AP; ORFNames=UNQ587/PRO1157;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   INTERACTION WITH PIK3R1 AND GRB2, AND PHOSPHORYLATION.
RX   PubMed=10528161;
RA   Chang C., Dietrich J., Harpur A.G., Lindquist J.A., Haude A., Loke Y.W.,
RA   King A., Colonna M., Trowsdale J., Wilson M.J.;
RT   "KAP10, a novel transmembrane adapter protein genetically linked to DAP12
RT   but with unique signaling properties.";
RL   J. Immunol. 163:4651-4654(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, INTERACTION WITH
RP   KLRK1 AND PIK3R1, GLYCOSYLATION, SUBCELLULAR LOCATION, PHOSPHORYLATION, AND
RP   MUTAGENESIS OF ASP-57.
RX   PubMed=10426994; DOI=10.1126/science.285.5428.730;
RA   Wu J., Song Y., Bakker A.B.H., Bauer S., Spies T., Lanier L.L.,
RA   Phillips J.H.;
RT   "An activating immunoreceptor complex formed by NKG2D and DAP10.";
RL   Science 285:730-732(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RX   PubMed=11398969; DOI=10.1007/s002510100321;
RA   Yim D., Jie H.-B., Sotiriadis J., Kim Y.-S., Kim K.-S., Rothschild M.F.,
RA   Lanier L.L., Kim Y.B.;
RT   "Molecular cloning and characterization of pig immunoreceptor DAP10 and
RT   NKG2D.";
RL   Immunogenetics 53:243-249(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Uterus;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, AND INTERACTION WITH KLRK1.
RX   PubMed=11015446; DOI=10.1084/jem.192.7.1059;
RA   Wu J., Cherwinski H., Spies T., Phillips J.H., Lanier L.L.;
RT   "DAP10 and DAP12 form distinct, but functionally cooperative, receptor
RT   complexes in natural killer cells.";
RL   J. Exp. Med. 192:1059-1068(2000).
RN   [8]
RP   FUNCTION.
RX   PubMed=11777960; DOI=10.4049/jimmunol.168.2.671;
RA   Sutherland C.L., Chalupny N.J., Schooley K., VandenBos T., Kubin M.,
RA   Cosman D.;
RT   "UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D
RT   and activate multiple signaling pathways in primary NK cells.";
RL   J. Immunol. 168:671-679(2002).
RN   [9]
RP   FUNCTION.
RX   PubMed=12740575; DOI=10.1038/ni929;
RA   Billadeau D.D., Upshaw J.L., Schoon R.A., Dick C.J., Leibson P.J.;
RT   "NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent
RT   regulatory pathway.";
RL   Nat. Immunol. 4:557-564(2003).
RN   [10]
RP   FUNCTION.
RX   PubMed=12740576; DOI=10.1038/ni930;
RA   Zompi S., Hamerman J.A., Ogasawara K., Schweighoffer E., Tybulewicz V.L.J.,
RA   Di Santo J.P., Lanier L.L., Colucci F.;
RT   "NKG2D triggers cytotoxicity in mouse NK cells lacking DAP12 or Syk family
RT   kinases.";
RL   Nat. Immunol. 4:565-572(2003).
RN   [11]
RP   INTERACTION WITH KLRK1.
RX   PubMed=15294961; DOI=10.4049/jimmunol.173.4.2470;
RA   Rosen D.B., Araki M., Hamerman J.A., Chen T., Yamamura T., Lanier L.L.;
RT   "A Structural basis for the association of DAP12 with mouse, but not human,
RT   NKG2D.";
RL   J. Immunol. 173:2470-2478(2004).
RN   [12]
RP   FUNCTION.
RX   PubMed=16002667; DOI=10.4049/jimmunol.175.2.720;
RA   Wiemann K., Mittruecker H.-W., Feger U., Welte S.A., Yokoyama W.M.,
RA   Spies T., Rammensee H.-G., Steinle A.;
RT   "Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in
RT   vivo.";
RL   J. Immunol. 175:720-729(2005).
RN   [13]
RP   FUNCTION.
RX   PubMed=16339517; DOI=10.4049/jimmunol.175.12.7819;
RA   Karimi M., Cao T.M., Baker J.A., Verneris M.R., Soares L., Negrin R.S.;
RT   "Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated
RT   CD8+ T cells and NK cells.";
RL   J. Immunol. 175:7819-7828(2005).
RN   [14]
RP   SUBUNIT.
RX   PubMed=15894612; DOI=10.1073/pnas.0502439102;
RA   Garrity D., Call M.E., Feng J., Wucherpfennig K.W.;
RT   "The activating NKG2D receptor assembles in the membrane with two signaling
RT   dimers into a hexameric structure.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:7641-7646(2005).
RN   [15]
RP   INDUCTION.
RX   PubMed=16424177; DOI=10.4049/jimmunol.176.3.1490;
RA   Burgess S.J., Marusina A.I., Pathmanathan I., Borrego F., Coligan J.E.;
RT   "IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T
RT   cells.";
RL   J. Immunol. 176:1490-1497(2006).
RN   [16]
RP   FUNCTION, INTERACTION WITH GRB2-VAV1 AND PIK3R1, PHOSPHORYLATION AT TYR-86,
RP   AND MUTAGENESIS OF ASN-88 AND MET-89.
RX   PubMed=16582911; DOI=10.1038/ni1325;
RA   Upshaw J.L., Arneson L.N., Schoon R.A., Dick C.J., Billadeau D.D.,
RA   Leibson P.J.;
RT   "NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and
RT   phosphatidylinositol-3-kinase in human natural killer cells.";
RL   Nat. Immunol. 7:524-532(2006).
RN   [17]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=18097042; DOI=10.4049/jimmunol.180.1.409;
RA   Marusina A.I., Burgess S.J., Pathmanathan I., Borrego F., Coligan J.E.;
RT   "Regulation of human DAP10 gene expression in NK and T cells by Ap-1
RT   transcription factors.";
RL   J. Immunol. 180:409-417(2008).
RN   [18]
RP   INTERACTION WITH CD300H.
RX   PubMed=26221034; DOI=10.1074/jbc.m115.643361;
RA   Niizuma K., Tahara-Hanaoka S., Noguchi E., Shibuya A.;
RT   "Identification and Characterization of CD300H, a New Member of the Human
RT   CD300 Immunoreceptor Family.";
RL   J. Biol. Chem. 290:22298-22308(2015).
CC   -!- FUNCTION: Transmembrane adapter protein which associates with KLRK1 to
CC       form an activation receptor KLRK1-HCST in lymphoid and myeloid cells;
CC       this receptor plays a major role in triggering cytotoxicity against
CC       target cells expressing cell surface ligands such as MHC class I chain-
CC       related MICA and MICB, and UL16-binding proteins (ULBPs); these ligands
CC       are up-regulated by stress conditions and pathological state such as
CC       viral infection and tumor transformation. Functions as a docking site
CC       for PI3-kinase PIK3R1 and GRB2. Interaction of ULBPs with KLRK1-HCST
CC       triggers calcium mobilization and activation of the PIK3R1, MAP2K/ERK,
CC       and JAK2/STAT5 signaling pathways. Both PIK3R1 and GRB2 are required
CC       for full KLRK1-HCST-mediated activation and ultimate killing of target
CC       cells. In NK cells, KLRK1-HCST signaling directly induces cytotoxicity
CC       and enhances cytokine production initiated via DAP12/TYROBP-associated
CC       receptors. In T-cells, it provides primarily costimulation for TCR-
CC       induced signals. KLRK1-HCST receptor plays a role in immune
CC       surveillance against tumors and is required for cytolysis of tumors
CC       cells; indeed, melanoma cells that do not express KLRK1 ligands escape
CC       from immune surveillance mediated by NK cells.
CC       {ECO:0000269|PubMed:10426994, ECO:0000269|PubMed:10528161,
CC       ECO:0000269|PubMed:11015446, ECO:0000269|PubMed:11777960,
CC       ECO:0000269|PubMed:12740575, ECO:0000269|PubMed:12740576,
CC       ECO:0000269|PubMed:16002667, ECO:0000269|PubMed:16339517,
CC       ECO:0000269|PubMed:16582911, ECO:0000269|PubMed:18097042}.
CC   -!- SUBUNIT: Interacts with CLEC5A (By similarity). Forms an
CC       CLEC5A/TYROBP/HCST trimolecular complex depending almost solely on
CC       TYROBP (By similarity). Homodimer; Disulfide-linked. Heterohexamer
CC       composed of four subunits of HCST/DAP10 and two subunits of KLRK1.
CC       Interacts (via transmembrane domain) with KLRK1 (via transmembrane
CC       domain); the interaction is required for KLRK1 NK cell surface and
CC       induces NK cell-mediated cytotoxicity. Interacts with PIK3R1 and GRB2.
CC       Interacts with CD300H (PubMed:26221034). {ECO:0000250,
CC       ECO:0000269|PubMed:10426994, ECO:0000269|PubMed:10528161,
CC       ECO:0000269|PubMed:11015446, ECO:0000269|PubMed:15294961,
CC       ECO:0000269|PubMed:15894612, ECO:0000269|PubMed:16582911,
CC       ECO:0000269|PubMed:26221034}.
CC   -!- INTERACTION:
CC       Q9UBK5; P23560-2: BDNF; NbExp=3; IntAct=EBI-2801937, EBI-12275524;
CC       Q9UBK5; Q96IW7: SEC22A; NbExp=3; IntAct=EBI-2801937, EBI-8652744;
CC       Q9UBK5; O95772: STARD3NL; NbExp=3; IntAct=EBI-2801937, EBI-3916943;
CC       Q9UBK5; Q6UX27-3: VSTM1; NbExp=3; IntAct=EBI-2801937, EBI-12190699;
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:10426994}; Single-
CC       pass type I membrane protein {ECO:0000269|PubMed:10426994}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9UBK5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UBK5-2; Sequence=VSP_033022;
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in hemopoietic cells such
CC       as NK cells, subset of T-cells and monocytes. Detected in leukocytes,
CC       spleen, and thymus. {ECO:0000269|PubMed:10528161}.
CC   -!- INDUCTION: By T-cell receptor (TCR) ligation, which leads to enhanced
CC       KLRK1-HCST cell surface expression. Down-regulated by IL21/interleukin-
CC       21 in T-cells and NK cells. {ECO:0000269|PubMed:16424177,
CC       ECO:0000269|PubMed:18097042}.
CC   -!- PTM: Phosphorylated; PIK3R1 and GRB2 associate specifically with
CC       tyrosine-phosphorylated HCST. {ECO:0000269|PubMed:10426994,
CC       ECO:0000269|PubMed:10528161, ECO:0000269|PubMed:16582911}.
CC   -!- PTM: O-glycosylated. {ECO:0000269|PubMed:10426994}.
CC   -!- MISCELLANEOUS: Silencing of HCST suppresses cytolytic activity of T-
CC       cells and NK cells.
CC   -!- SIMILARITY: Belongs to the DAP10 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF172929; AAD50293.1; -; mRNA.
DR   EMBL; AF072844; AAD46986.1; -; mRNA.
DR   EMBL; AF072845; AAD46987.1; -; Genomic_DNA.
DR   EMBL; AF122904; AAD47911.1; -; mRNA.
DR   EMBL; AF285447; AAG29425.1; -; mRNA.
DR   EMBL; AY359058; AAQ89417.1; -; mRNA.
DR   EMBL; AL050163; CAB43303.2; -; mRNA.
DR   EMBL; BC035931; AAH35931.1; -; mRNA.
DR   EMBL; BC046348; AAH46348.1; -; mRNA.
DR   EMBL; BC065224; AAH65224.1; -; mRNA.
DR   CCDS; CCDS32998.1; -. [Q9UBK5-1]
DR   CCDS; CCDS46057.1; -. [Q9UBK5-2]
DR   PIR; T08788; T08788.
DR   RefSeq; NP_001007470.1; NM_001007469.2. [Q9UBK5-2]
DR   RefSeq; NP_055081.1; NM_014266.4. [Q9UBK5-1]
DR   AlphaFoldDB; Q9UBK5; -.
DR   SMR; Q9UBK5; -.
DR   BioGRID; 116079; 231.
DR   CORUM; Q9UBK5; -.
DR   FunCoup; Q9UBK5; 196.
DR   IntAct; Q9UBK5; 203.
DR   STRING; 9606.ENSP00000246551; -.
DR   iPTMnet; Q9UBK5; -.
DR   PhosphoSitePlus; Q9UBK5; -.
DR   BioMuta; HCST; -.
DR   DMDM; 74734930; -.
DR   MassIVE; Q9UBK5; -.
DR   PaxDb; 9606-ENSP00000246551; -.
DR   PeptideAtlas; Q9UBK5; -.
DR   ProteomicsDB; 83979; -. [Q9UBK5-1]
DR   ProteomicsDB; 83980; -. [Q9UBK5-2]
DR   Antibodypedia; 29605; 155 antibodies from 21 providers.
DR   DNASU; 10870; -.
DR   Ensembl; ENST00000246551.9; ENSP00000246551.3; ENSG00000126264.10. [Q9UBK5-1]
DR   Ensembl; ENST00000437550.2; ENSP00000400516.1; ENSG00000126264.10. [Q9UBK5-2]
DR   GeneID; 10870; -.
DR   KEGG; hsa:10870; -.
DR   MANE-Select; ENST00000246551.9; ENSP00000246551.3; NM_014266.4; NP_055081.1.
DR   UCSC; uc002ock.2; human. [Q9UBK5-1]
DR   AGR; HGNC:16977; -.
DR   CTD; 10870; -.
DR   DisGeNET; 10870; -.
DR   GeneCards; HCST; -.
DR   HGNC; HGNC:16977; HCST.
DR   HPA; ENSG00000126264; Tissue enhanced (bone marrow, lymphoid tissue).
DR   MIM; 604089; gene.
DR   OpenTargets; ENSG00000126264; -.
DR   VEuPathDB; HostDB:ENSG00000126264; -.
DR   eggNOG; ENOG502TKP3; Eukaryota.
DR   GeneTree; ENSGT00390000012777; -.
DR   HOGENOM; CLU_196934_0_0_1; -.
DR   InParanoid; Q9UBK5; -.
DR   OMA; AQMTPGE; -.
DR   PAN-GO; Q9UBK5; 3 GO annotations based on evolutionary models.
DR   PhylomeDB; Q9UBK5; -.
DR   PathwayCommons; Q9UBK5; -.
DR   Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   SignaLink; Q9UBK5; -.
DR   BioGRID-ORCS; 10870; 14 hits in 1141 CRISPR screens.
DR   ChiTaRS; HCST; human.
DR   GeneWiki; HCST_(gene); -.
DR   GenomeRNAi; 10870; -.
DR   Pharos; Q9UBK5; Tbio.
DR   PRO; PR:Q9UBK5; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q9UBK5; protein.
DR   Bgee; ENSG00000126264; Expressed in granulocyte and 155 other cell types or tissues.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProt.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IDA:UniProtKB.
DR   GO; GO:0030674; F:protein-macromolecule adaptor activity; IDA:UniProt.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:UniProtKB.
DR   GO; GO:0042267; P:natural killer cell mediated cytotoxicity; IDA:UniProt.
DR   GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IGI:CACAO.
DR   GO; GO:0050776; P:regulation of immune response; IEA:InterPro.
DR   InterPro; IPR009861; HCST.
DR   PANTHER; PTHR21409; HEMATOPOIETIC CELL SIGNAL TRANSDUCER; 1.
DR   PANTHER; PTHR21409:SF1; HEMATOPOIETIC CELL SIGNAL TRANSDUCER; 1.
DR   Pfam; PF07213; DAP10; 2.
DR   neXtProt; NX_Q9UBK5; -.
DR   PharmGKB; PA134956649; -.
DR   TreeFam; TF338335; -.
PE   1: Evidence at protein level;
KW   Alternative splicing; Disulfide bond; Glycoprotein; Membrane;
KW   Phosphoprotein; Proteomics identification; Reference proteome; Signal;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL          1..18
FT                   /evidence="ECO:0000255"
FT   CHAIN           19..93
FT                   /note="Hematopoietic cell signal transducer"
FT                   /id="PRO_0000330287"
FT   TOPO_DOM        19..48
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        49..69
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        70..93
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          86..89
FT                   /note="PIK3R1 binding site"
FT   REGION          86..88
FT                   /note="GRB2 binding site"
FT   MOD_RES         86
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:16582911"
FT   VAR_SEQ         81
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10426994,
FT                   ECO:0000303|PubMed:12975309"
FT                   /id="VSP_033022"
FT   MUTAGEN         57
FT                   /note="D->A: Abolishes stable interaction with KLRK1."
FT                   /evidence="ECO:0000269|PubMed:10426994"
FT   MUTAGEN         88
FT                   /note="N->Q: Abrogates cell killing and interaction with
FT                   GRB2. No effect on interaction with PIK3R1."
FT                   /evidence="ECO:0000269|PubMed:16582911"
FT   MUTAGEN         89
FT                   /note="M->Q: Abrogates cell killing and interaction with
FT                   PIK3R1. No effect on interaction with GRB2."
FT                   /evidence="ECO:0000269|PubMed:16582911"
SQ   SEQUENCE   93 AA;  9489 MW;  97786F24F8A2EE44 CRC64;
     MIHLGHILFL LLLPVAAAQT TPGERSSLPA FYPGTSGSCS GCGSLSLPLL AGLVAADAVA
     SLLIVGAVFL CARPRRSPAQ EDGKVYINMP GRG
//
